Propanc Health Group Corp (OTCMKTS:PPCH) is consolidating well since the explosive move up it made in recent days. The stock has skyrocketed in recent months quickly transforming into one of the top traded stocks on the entire bb’s on heavy promotion from an Investment Newsletter called the Wealthy Biotech Trader as well as a paid feature in the NY Times Sunday Edition Magazine under Health Essentials: Cancer Prevention & Treatment on April 19th.
PPCH is focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with their scientific and oncology consultants, they have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body.
Propanc Health Group Corp (OTCMKTS:PPCH) lead drug candidate, PRP, is a once-daily pro-enzyme treatment as a clinically proven therapeutic option in the treatment and prevention of cancer. PRP would be the first therapy of its kind, as there are no FDA approved therapies used for the long-term prevention or management of these conditions. Propanc is focusing on providing oncologists and their patients with more effective metastatic cancer therapies with a substantially reduced side effect profile; specifically, colorectal and pancreatic cancers. Improvement is needed for the standard of care for late stage cancer, with the incumbent treatments causing significant adverse effects for the modest benefits provided.
Propanc is seeking potential licensing partners within the next 12-18 months and the Company is also investigating acquisition opportunities that will expedite their strategic growth and strengthen their portfolio. Company management has stated that once the development projects have sufficiently progressed down the development pathway and have commensurately achieved a major increase in value, they will seek a suitable licensing partner to complete the remaining development activities, obtain regulatory approval and market the product.
To Find out the inside Scoop on PPCH Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Propanc recently filed an international patent application centered on enhancing pro-enzyme formulations and combination therapies comprising trypsinogen and chymotrypsin, and/or other specific anti-cancer agents.
On May 5 PPCH announced Game Changing News when they announced the first set of results from its series of animal studies, with PRP showing no adverse clinical signs at the maximum tolerated dose (MTD) in mice when administered by I.V injection. The MTD is more than twice the human equivalent dose administered to patients at the Dove Clinic for compassionate use.
Prior to the MTD mice study, the two proenzymes were individually assessed to measure activity in cell culture studies, with both active ingredients displaying inhibitory activity in pancreatic and ovarian cancer cell lines.
PPCH Chief Scientific Officer Dr Julian Kenyon said “These findings are significant, because it gives us confidence that PRP appears to be safe and tolerable when administered by I.V injection at higher doses. Furthermore, we can now presume one hundred percent of the drug has been absorbed into the bloodstream. This is not the case when I first treated patients with proenzymes with a suppository formulation at the Dove Clinic, which is expected to have a lower absorption rate.”
PPCH has some big names behind it; Klaus Kutz, CMO of Propanc has prepared multiple investigational new drugs (IND) FDA applications for Sanofi, a $48 stock. Dr. Ralph Brandt of Propanc successfully led the tumor biology program for animal studies at Novartis. Novartis is now trading at $98 a share.
On June 16 The Wealthy Biotech Trader announced it would like to report on the seldom huge potential of the OTC market when used as a proper stepping-stone to a national stock exchange.
Very seldom do you see long-term success in the sometimes scary OTC market. One might gauge long-term success as assembling a world class management team, raising some capital on not-so-good terms, and bringing a business plan to the point where it’s considered a valuable asset. Down this road, there are many more things that can go wrong than can go right. The proverbial pot of gold at the end of the rainbow would be the infamous “up-listing” to the NASDAQ or the NYSE-by way of achieving the aforementioned goals, but also quantifiable goals like share price and book value increases. It’s not an easy task.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $40 million market valuation PPCH has no revenues to date, minimal assets and significant rising short term debt. But this is an exciting story that is taking the small caps by storm; this tiny biotech is developing new cancer treatments that could blow this story wide open. We will be updating on PPCH on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with PPCH.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in PPCH either long or short and we have not been compensated for this article.